AXS-05 Results in Reduction in Major Depression Symptoms

Via Peters

New data indicates a positive future for AXS-05 (dextromethorphan-bupropion) as a potential treatment for patients with major depressive disorder. The drug, developed by Axsome Therapeutics, is a novel, oral investigational N-methyl-D-aspartate (NMDA) receptor antagonist with multimodal activity. The results from the GEMINI phase 3 clinical trial show AXS-05 showed rapid, […]